Interim data show that AU-011 has been generally well-tolerated in the multiple ascending dose cohort of the ongoing clinical trial.
Interim data presented today show that AU-011 has been generally well-tolerated, and early efficacy results are very promising.
Aura announced that it has closed $30 million in Series C financing, which will support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing
Aura announced that researchers at Massachusetts Eye and Ear (MEE), Emory University and the National Cancer Institute (NCI) have generated preclinical data that demonstrate the ability of light-activated AU-011 to target and selectively destroy ocular melanoma tumors.
Molecular Cancer Therapeutics
Kines R, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang S, Grossniklaus H, Vavvas D, Monks S, MacDougall J, de los Pinos E, Schiller J
Aura announced that Cadmus Rich, M.D., has joined the company’s leadership team as Chief Medical Officer.
Interim Phase 1b/2 data on AU-011 presented by Carol Shields, M.D., at AAO 2017 show safety and preliminary efficacy at three months post-treatment.
Carol Shields, M.D., of the Wills Eye Hospital in Philadelphia, will present data from Aura's Phase 1b clinical safety study of AU-011 at AAO 2017.
National Institutes of Health
American Academy of Ophthalmology
Aura has enrolled and dosed at Wills Eye Hospital the first patient in its Phase 1b clinical trial of AU-011. The company also has received FDA fast track designation for AU-011 for the treatment of primary ocular melanoma.
Aura has received IND clearance from the U.S. FDA for its lead program, light-activated AU-011 in ocular melanoma (OM). This active IND enables Aura to begin initial clinical testing of AU-011, a unique targeted therapy that could transform the primary treatment of patients with OM.
Kaliki S and Shields C L
Aura secured an additional $8 million round of funding to advance AU-011 to the clinic. The company also announced the addition of Henri Termeer, former CEO of Genzyme and major Aura investor, to its Board of Directors, and welcomed key new Clinical Advisory Board (CAB) members, all distinguished ocular oncologists.